KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2024 Jul 8

PMID 38973255

Authors

Zhiyan Zhan

Jiarong Zhang

Huisheng Liang

Chong Wang

Li Hong

Wenxue Liu

Affiliations

Soon will be listed here.

Abstract

Most clinical PARP inhibitors (PARPis) trap PARP1 in a chromatin-bound state, leading to PARPi-mediated cytotoxicity. PARPi resistance impedes the treatment of ovarian cancer in clinical practice. However, the mechanism by which cancer cells overcome PARP1 trapping to develop PARPi resistance remains unclear. Here, it is shown that high levels of KAT6A promote PARPi resistance in ovarian cancer, regardless of its catalytic activity. Mechanistically, the liquid-liquid phase separation (LLPS) of KAT6A, facilitated by APEX1, inhibits the cytotoxic effects of PARP1 trapping during PARPi treatment. The stable KAT6A-PARP1-APEX1 complex reduces the amount of PARP1 trapped at the DNA break sites. In addition, inhibition of KAT6A LLPS, rather than its catalytic activity, impairs DNA damage repair and restores PARPi sensitivity in ovarian cancer both in vivo and in vitro. In conclusion, the findings demonstrate the role of KAT6A LLPS in fostering PARPi resistance and suggest that repressing KAT6A LLPS can be a potential therapeutic strategy for PARPi-resistant ovarian cancer.

Citing Articles

The Trim32-DPEP2 axis is an inflammatory switch in macrophages during intestinal inflammation.

Zhan Z, Liang H, Zhao Z, Pan L, Li J, Chen Y Cell Death Differ. 2025; .

PMID: 40021897 DOI: 10.1038/s41418-025-01468-w.

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.

Zhan Z, Zhang J, Liang H, Wang C, Hong L, Liu W Adv Sci (Weinh). 2024; 11(34):e2400140.

PMID: 38973255 PMC: 11425913. DOI: 10.1002/advs.202400140.

References

Linding R, Jensen L, Diella F, Bork P, Gibson T, Russell R . Protein disorder prediction: implications for structural proteomics. Structure. 2003; 11(11):1453-9. DOI: 10.1016/j.str.2003.10.002. View

Pettitt S, Rehman F, Bajrami I, Brough R, Wallberg F, Kozarewa I . A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520. PMC: 3636235. DOI: 10.1371/journal.pone.0061520. View

Paes Dias M, Moser S, Ganesan S, Jonkers J . Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021; 18(12):773-791. DOI: 10.1038/s41571-021-00532-x. View

Baell J, Leaver D, Hermans S, Kelly G, Brennan M, Downer N . Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018; 560(7717):253-257. DOI: 10.1038/s41586-018-0387-5. View

Fantini D, Vascotto C, Marasco D, DAmbrosio C, Romanello M, Vitagliano L . Critical lysine residues within the overlooked N-terminal domain of human APE1 regulate its biological functions. Nucleic Acids Res. 2010; 38(22):8239-56. PMC: 3001066. DOI: 10.1093/nar/gkq691. View

Su J, Wang X, Bai Y, Sun M, Yao Y, Duan Y . The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors. Pharmacol Res. 2021; 174:105930. DOI: 10.1016/j.phrs.2021.105930. View

Duster R, Kaltheuner I, Schmitz M, Geyer M . 1,6-Hexanediol, commonly used to dissolve liquid-liquid phase separated condensates, directly impairs kinase and phosphatase activities. J Biol Chem. 2021; 296:100260. PMC: 7948595. DOI: 10.1016/j.jbc.2021.100260. View

Tong X, Tang R, Xu J, Wang W, Zhao Y, Yu X . Liquid-liquid phase separation in tumor biology. Signal Transduct Target Ther. 2022; 7(1):221. PMC: 9270353. DOI: 10.1038/s41392-022-01076-x. View

Krastev D, Li S, Sun Y, Wicks A, Hoslett G, Weekes D . The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat Cell Biol. 2022; 24(1):62-73. PMC: 8760077. DOI: 10.1038/s41556-021-00807-6. View

10.

Zhan Z, Zhang J, Liang H, Wang C, Hong L, Liu W . KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer. Adv Sci (Weinh). 2024; 11(34):e2400140. PMC: 11425913. DOI: 10.1002/advs.202400140. View

11.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

12.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

13.

Nakamura T, Hipp C, Mourao A, Borggrafe J, Aldrovandi M, Henkelmann B . Phase separation of FSP1 promotes ferroptosis. Nature. 2023; 619(7969):371-377. PMC: 10338336. DOI: 10.1038/s41586-023-06255-6. View

14.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

15.

Sabari B, DallAgnese A, Boija A, Klein I, Coffey E, Shrinivas K . Coactivator condensation at super-enhancers links phase separation and gene control. Science. 2018; 361(6400). PMC: 6092193. DOI: 10.1126/science.aar3958. View

16.

Zu G, Liu Y, Cao J, Zhao B, Zhang H, You L . BRPF1-KAT6A/KAT6B Complex: Molecular Structure, Biological Function and Human Disease. Cancers (Basel). 2022; 14(17). PMC: 9454415. DOI: 10.3390/cancers14174068. View

17.

Yan K, Rousseau J, Machol K, Cross L, Agre K, Gibson C . Deficient histone H3 propionylation by BRPF1-KAT6 complexes in neurodevelopmental disorders and cancer. Sci Adv. 2020; 6(4):eaax0021. PMC: 6976298. DOI: 10.1126/sciadv.aax0021. View

18.

Li M, Wilson 3rd D . Human apurinic/apyrimidinic endonuclease 1. Antioxid Redox Signal. 2013; 20(4):678-707. PMC: 3901322. DOI: 10.1089/ars.2013.5492. View

19.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

20.

Largeot A, Paggetti J, Broseus J, Aucagne R, Lagrange B, Martin R . Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells. Biochim Biophys Acta. 2013; 1833(12):3054-3063. DOI: 10.1016/j.bbamcr.2013.08.013. View